Wednesday, March 03, 2021 8:24:57 AM
Recent OVID News
- Ovid Therapeutics to Host Investor Event • GlobeNewswire Inc. • 10/31/2024 12:00:00 PM
- Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin • GlobeNewswire Inc. • 09/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:38:01 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:36:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 08:57:01 PM
- Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth • GlobeNewswire Inc. • 09/11/2024 12:00:00 PM
- Ovid Therapeutics to Present at Upcoming September Investor Conferences • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:02:49 PM
- Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 09:22:46 PM
- Ovid Therapeutics to Present at Upcoming August Investor Conferences • GlobeNewswire Inc. • 07/30/2024 12:00:00 PM
- Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:10:10 AM
- Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat • GlobeNewswire Inc. • 06/17/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:22:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/14/2024 09:19:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:03:02 PM
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
FEATURED DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • Nov 7, 2024 2:16 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM